NCT00083694View on ClinicalTrials.gov

Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia

PHASE2CompletedINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

August 31, 1998

Study Completion Date

May 31, 2005

Conditions

Leukemia

Interventions

DRUG

Thalidomide

Trial Locations (1)

72205

University of Arkansas for Medical Sciences/MIRT, Little Rock

Sponsors

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

Celgene Corporation

INDUSTRY

lead

University of Arkansas

OTHER